Suppr超能文献

同质多发性硬化队列的全基因组关联研究:瘤样脱髓鞘病变

Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination.

作者信息

Zhao-Fleming Hannah H, Decker Paul A, Kosel Matthew L, Drucker Kristen L, Kollmeyer Thomas, Lachance Daniel H, Clarkson Benjamin D, Howe Charles L, Jenkins Robert, Tobin W Oliver, Eckel-Passow Jeanette

机构信息

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.

出版信息

Mult Scler. 2025 Sep 8:13524585251371984. doi: 10.1177/13524585251371984.

Abstract

BACKGROUND

Tumefactive demyelination (TD) is a rare variant of multiple sclerosis (MS) characterized by tumor-like lesions that often require aggressive management. Genome-wide association studies (GWAS) identified variants associated with MS; similar analyses in TD are lacking.

OBJECTIVE

A GWAS was performed to identify variants associated with TD.

METHODS

The case-control study included 142 TD cases and 293 controls. TD patients were required to have a demyelinating event and magnetic resonance imaging (MRI) showing one or more lesions. Controls were patients without a neurologic or systemic inflammatory disease or cancer. Logistic regression was used to compare cases versus controls for each variant; age, sex, and principal components were included as covariates. A -value threshold of 5 × 10 was GWAS significant and 5 × 10 nominally significant. A polygenic risk score (PRS) was compared across TD and controls.

RESULTS

Variants on chromosome 14 (rs117797734,  = 2.06 × 10, odds ratio (OR) = 13.14) and chromosome 6 (most significant rs6936540,  = 5.5 × 10, OR = 2.61) near were significant. Seven non-MHC and two MHC variants associated with MS were associated with TD. The PRS was significantly higher in TD versus controls.

CONCLUSION

We identified novel regions associated with TD, demonstrating the importance of performing GWAS in homogeneous subtypes of MS. Further validation and functional experiments are necessary.

摘要

背景

瘤样脱髓鞘病变(TD)是多发性硬化症(MS)的一种罕见变异型,其特征为肿瘤样病变,通常需要积极治疗。全基因组关联研究(GWAS)已确定与MS相关的变异;但缺乏对TD进行类似分析。

目的

进行一项GWAS以确定与TD相关的变异。

方法

病例对照研究纳入了142例TD病例和293例对照。TD患者需有脱髓鞘事件且磁共振成像(MRI)显示一个或多个病变。对照为无神经或全身性炎症性疾病或癌症的患者。采用逻辑回归比较每个变异的病例与对照;将年龄、性别和主成分作为协变量纳入。P值阈值为5×10⁻⁸为GWAS显著,5×10⁻⁵为名义上显著。比较了TD和对照之间的多基因风险评分(PRS)。

结果

14号染色体上的变异(rs117797734,P = 2.06×10⁻⁸,比值比(OR)= 13.14)和6号染色体上靠近的变异(最显著的rs6936540,P = 5.5×10⁻⁷,OR = 2.61)具有显著性。七个与MS相关的非MHC和两个MHC变异与TD相关。TD的PRS显著高于对照。

结论

我们确定了与TD相关的新区域,证明了在MS的同质亚型中进行GWAS的重要性。进一步的验证和功能实验是必要的。

相似文献

6
Rapamycin and rapalogs for tuberous sclerosis complex.用于结节性硬化症的雷帕霉素及雷帕霉素类似物。
Cochrane Database Syst Rev. 2016 Jul 13;7(7):CD011272. doi: 10.1002/14651858.CD011272.pub2.
9
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3.
10
Dimethyl fumarate for multiple sclerosis.富马酸二甲酯用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2015 Apr 22;2015(4):CD011076. doi: 10.1002/14651858.CD011076.pub2.

本文引用的文献

7
Polygenic risk scores and breast cancer risk prediction.多基因风险评分与乳腺癌风险预测。
Breast. 2023 Feb;67:71-77. doi: 10.1016/j.breast.2023.01.003. Epub 2023 Jan 10.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验